Author:
Torti Carlo,Lapadula Giuseppe,Uccelli Maria Cristina,Quiros-Roldan Eugenia,Regazzi Mario,Ladisa Nicoletta,Micheli Valeria,Orani Anna,Patroni Andrea,Caputo Sergio Lo,Tirelli Valeria,Di Giambenedetto Simona,Cologni Giuliana,Costarelli Silvia,Gargiulo Franco,Manca Nino,Carosi Giampiero
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine
Reference35 articles.
1. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy;Boffito;Antivir Ther,2005
2. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV–hepatitis C virus-coinfected subjects;Regazzi;Antimicrob Agents Chemother,2005
3. High indinavir plasma concentrations in HIV-positive patients co-infected with hepatitis B or C virus treated with low doses of indinavir and ritonavir (400/100mg twice a day) plus two nucleoside reverse transcriptase inhibitors;Bossi;AIDS,2003
4. Arribas J, Pulido F, Peng JZ, et al. Evaluation of multiple-dose pharmacokinetics of lopinavir/ritonavir (LPV/R) in HIV and HCV coinfected subjects with mild or moderate hepatic insufficiency. In: 9th European AIDS Conference; Warsaw; October 2003 [F2-F6].
5. Dickinson L, Micheli V, Meraviglia P, et al. The impact of co-infection with hepatitis C or hepatitis B on lopinavir pharmacokinetics in patients infected with HIV. In: 3rd IAS Conference on HIV Pathogenesis and Treatment; Rio de Janeiro; July 2005 [WePe3.2C06].
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献